Radioactive drug trial offers new hope for men with Tough-to-Treat prostate cancer
Disease control
Completed
This study tested whether adding a radioactive drug (I-131-1095) to standard medication (enzalutamide) could better control advanced prostate cancer that had worsened on a prior drug (abiraterone). It involved 120 men whose cancer had spread and was visible on a special PSMA scan…
Phase: PHASE2 • Sponsor: Progenics Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC